SixPeaks Snags $110M from Versant, AZ for Drugs to Preserve Muscle and Shed Fat

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Santa Ana Bio Debuts with $168M to Develop Precision Inflammatory Medicines
Versant-Backed Nexo Gets $60M to Pursue Tough Cancer Targets
Startup Profiles: Upstream Bio Gets Another $200M, Kate Therapeutics Debuts with $51M
Abdera Gets $142M To Make Potent, Safe, Radioantibodies for Cancer